Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.38 |
| ▸ | PPARA | Q07869 | 11/20 | 0.38 |
| ▸ | PPARD | Q03181 | 7/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 8/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 8/20 | 0.35 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375529 | 1.00 | PPARG (0.38) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4388960 | 0.96 | PPARG (0.40) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4389972 | 0.96 | PPARG (0.40) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4483727 | 0.96 | PPARG (0.40) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4378274 | 0.91 | PPARA (0.36) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4383910 | 0.90 | SLC16A3 (0.42) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL4389989 | 0.90 | SLC16A3 (0.42) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL4377292 | 0.90 | PPARA (0.40) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4380740 | 0.89 | PPARA (0.45) | PPARGPPARAPPARD | |
| SCHEMBL4386898 | 0.89 | PPARA (0.45) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789402-B1 | 2-{-3-2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL!-CYCLOHEXYLMETHOXY };-PROPIONIC ACID DERIVATIVES USED AS PPAR LIGANDES (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS) FOR THE TREATMENT OF HYPERLIPIDAEMIE AND DIABETES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-11-18 | — | — | EP | disclosed |